We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

220 hedge funds and large institutions have $2.44B invested in Immunomedics Inc in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 65 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $28.6M | Put options by funds: $15.9M

25% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 65

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

10% less funds holding

Funds holding: 245220 (-25)

33% less capital invested

Capital invested by funds: $3.65B → $2.44B (-$1.22B)

39% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 54

Holders
220
Holders Change
-25
Holders Change %
-10.2%
% of All Funds
4.85%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.15%
New
33
Increased
81
Reduced
65
Closed
54
Calls
$28.6M
Puts
$15.9M
Net Calls
+$12.7M
Net Calls Change
-$36.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
26
Franklin Resources
California
$24.2M +$1.47M +87,300 +5%
Norges Bank
27
Norges Bank
Norway
$23.1M -$1.1M -65,490 -4%
PAMU
28
Pictet Asset Management (UK)
United Kingdom
$18.6M +$1.45M +86,031 +7%
FCM
29
Frontier Capital Management
Massachusetts
$16.7M +$714K +42,460 +4%
Charles Schwab
30
Charles Schwab
California
$16.6M +$986K +58,623 +5%
PHS
31
PFM Health Sciences
California
$14.3M -$7.32M -435,198 -29%
RHJA
32
Rice Hall James & Associates
California
$14.3M +$161K +9,543 +0.9%
Goldman Sachs
33
Goldman Sachs
New York
$14.2M -$10.8M -642,493 -38%
RSCM
34
Rock Springs Capital Management
Maryland
$14.2M +$841K +50,000 +5%
GTC
35
Ghost Tree Capital
New York
$14.2M +$9.25M +550,000 +110%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$11.8M +$371K +22,040 +3%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$11.4M +$477K +28,320 +3%
CS
38
Candriam SCA
Luxembourg
$11.1M +$623 +37 +0%
N
39
Nuveen
North Carolina
$10.5M +$1.11M +66,216 +9%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$10.4M +$5.05K +300 +0%
SAM
41
Sectoral Asset Management
Quebec, Canada
$10.3M +$1.18M +70,000 +10%
PCM
42
Peregrine Capital Management
Minnesota
$10.2M +$1.18M +70,402 +10%
Bank of America
43
Bank of America
North Carolina
$9.08M -$2.74M -162,966 -19%
Loomis, Sayles & Company
44
Loomis, Sayles & Company
Massachusetts
$8.14M +$1.78M +106,040 +21%
RPAM
45
Rhenman & Partners Asset Management
Sweden
$7.95M -$1.85M -110,000 -16%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$7.81M +$5.68M +337,788 +140%
UBS AM
47
UBS AM
Illinois
$7.64M -$1.36M -80,831 -12%
Invesco
48
Invesco
Georgia
$7.35M +$477K +28,373 +5%
MWNA
49
Marshall Wace North America
New York
$7.03M +$8.39M +498,916 +2,216%
GIM
50
Granahan Investment Management
Massachusetts
$7.01M +$1.51M +89,706 +21%

IMMU Hedge Fund Activity: Q1 2020 in Review

220 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2020, worth a combined $2.44B — down 33% from $3.65B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of IMMU and 33 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 81 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $58.9M. The largest seller was Foresite Capital Management III, cutting an estimated $22.7M.

  • 220 institutional investors held Immunomedics Inc (IMMU) as of Q1 2020, down from 245 in Q4 2019.
  • Funds reported $2.44B of Immunomedics Inc stock for Q1 2020, down 33% quarter-over-quarter.
  • 33 funds opened new Immunomedics Inc positions in Q1 2020 and 54 closed out, a net change of -21 holders.
  • The largest Immunomedics Inc buyer in Q1 2020 was Point72 Asset Management, an estimated $58.9M added.
  • The largest Immunomedics Inc seller in Q1 2020 was Foresite Capital Management III, an estimated $22.7M sold.

Based on aggregated 13F filings for Q1 2020.